LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics Plc [http://silence-therapeutics.com ] (AIM: SLN), a leading international RNAi therapeutics company [http://silence-therapeutics.com/pipeline/clinical-programs/#!/about-us

LONDON, September 21, 2011 /PRNewswire/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and

LONDON, April 27, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its results for the year ended 31 December 2010. Analyst Conference Call: There will be a call for analysts today at 14:30 BST / 09:30 ET.

LONDON, April 29 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces its results for the year ended 31 December 2009. On 5 January 2010, Silence merged with U.S.-based RNA interference (RNAi) therapeutic company, Intradigm Corporation, to form a leading company in the field of RNAi.

LONDON, April 13 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the Company is executing a strategic plan designed to optimally organize its resources following its recent merger with Intradigm Corporation.